Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic ...
The Pharma Letter2d
Alexion Pharmaceuticals
Alexion Pharmaceuticals (NASDAQ: ALXN) is a US-headquartered biopharmaceutical company focused on developing and delivering therapies for patients with severe and life-threatening diseases. Alexion ...
pharmaphorum2d
Alexion finally has a buyer – and it's AstraZeneca with $39bn on the table
Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...
Channel NewsAsia Singapore2d
Singapore, South Korea launch logo marking 50 years of diplomatic relations
SINGAPORE: Singapore and South Korea launched a logo to be used in events celebrating the 50th anniversary of diplomatic relations between the two countries. The logo, unveiled on Monday (Jan 13 ...
pharmaphorum5d
Kanuma approval adds to Alexion rare disease roster
Alexion has gained FDA approval for Kanuma, its treatment for the rare disease lysosomal acid lipase (LAL) deficiency. Alexion says Kanuma (sebelipase alfa) could eventually bring in more than $ ...
TMCnet6d
Serna Bio Announces Scientific Advisory Board
Seasoned advisory group including RNA, translation and commercialisation luminaries.